Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $41.74M (cash outflow) rose 5.3% year over year, behind the +126.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 30.5% from the prior quarter. Over 3 fiscal years it compounded at +10.3% a year.
Context
- Free cash flow amounted to 509.6% of revenue in FY2025, up 488.4 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.3% toward the trailing-twelve-month pace of +126.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (129.55M) USD
- Year-over-year change
- -189.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.55M) | -189.7% |
| FY2024 | 2024-12-31 | (44.72M) | -133.3% |
| FY2023 | 2023-12-31 | 134.19M | +238.8% |
| FY2022 | 2022-12-31 | (96.67M) | -74.4% |
| FY2021 | 2021-12-31 | (55.44M) | — |
Free Cash Flow vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 free cash flow of $131.64M is the 2nd largest of the 11 companies compared; the peer median is $105.95M.
- Its year-over-year change of +126.9% is the 2nd highest of 11, against a peer median of +7.8%.
- Free cash flow amounts to 2294.2% of revenue for TRDA, versus a peer median of 243.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +2.4% | — | |
| LTM Mar 2026 | $131.64M | +126.9% | +10.3% | 2294.2% | |
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Mar 2026 | $127.3M | +121.8% | — | 58.5% | |
| LTM Mar 2026 | $113.96M | +141.6% | — | — | |
| LTM Mar 2026 | $109.53M | -44.7% | -12.8% | — | |
| LTM Mar 2026 | $102.38M | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $58.89M | -34.5% | — | 129.9% | |
| LTM Mar 2026 | $49.91M | -7.0% | +0.5% | — | |
| LTM Mar 2026 | $45.31M | +27.4% | +9.6% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| Peer median (excluding TRDA) | $105.95M | +7.8% | +9.6% | 243.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.